Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

President Donald Trump announced on Friday a deal with drugmaker AstraZeneca in his latest effort to lower drug costs through so-called “Most Favored Nation” pricing. The move comes after the ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

LONDON (Reuters) - U.S. drugmaker Pfizer Inc increased its offer for AstraZeneca Plc to 63 billion pounds ($106 billion) on Friday, but the British company promptly rejected the proposal, which would ...

Pfizer's oncology sales rose 9% in H1 2025, while AstraZeneca's jumped 16% in the same period. Pfizer offers a 7.1% dividend yield, but faces looming patent losses and IRA headwinds. AstraZeneca ...

AstraZeneca made a commitment to sell the shot developed with Oxford University at cost during the pandemic and in a press ...